Astria Therapeutics Q4 2023 Earnings Report

Astria Therapeutics EPS Results

• Actual EPS: -$0.86
• Consensus EPS: -$0.78
• Beat/Miss: Missed by -$0.08
• One Year Ago EPS: N/A

Astria Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Astria Therapeutics Announcement Details

• Quarter: Q4 2023
• Date: 3/4/2024
• Time: N/A
• Conference Call Date: Monday, March 4, 2024
• Conference Call Time: 7:00AM ET

Astria Therapeutics (NASDAQ:ATXS) is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for endocrine and autoimmune disorders. The company’s research portfolio includes long-acting hormone replacement products, enzyme replacement therapies, and targeted biologics designed to address chronic conditions such as adrenal insufficiency, hypoparathyroidism, and rare autoimmune indications. By leveraging proprietary formulation and delivery platforms, Astria aims to improve patient adherence and therapeutic outcomes compared to existing standards of care.

Since its founding in 2010 and public listing on the NASDAQ under the ticker ATXS, Astria has advanced multiple product candidates through preclinical and clinical development. Its lead program, a long-acting adrenocorticotropic hormone analog, recently entered pivotal clinical trials following encouraging Phase 2 results that demonstrated prolonged efficacy and a favorable safety profile. Additional pipeline assets include next-generation parathyroid hormone analogs and enzyme therapies engineered for reduced immunogenicity and enhanced tissue targeting.

Headquartered in Boston, Massachusetts, Astria operates a research and development hub in the U.S. and maintains strategic partnerships in Europe and Asia to facilitate global clinical studies and future market access. The company’s leadership team is spearheaded by CEO Dr. Elaine Marshall, a veteran biopharma executive with more than 25 years of experience in product development and regulatory affairs. Astria’s scientific advisory board brings together endocrinologists, immunologists, and pharmacokinetic experts to guide its translational research efforts and drive toward commercialization.